Assuntos
Anafilaxia/induzido quimicamente , Anticorpos Anti-Idiotípicos/efeitos adversos , Anticorpos Monoclonais Humanizados/efeitos adversos , Hipersensibilidade a Drogas/etiologia , Doença do Soro/etiologia , Anafilaxia/epidemiologia , Canadá , Hipersensibilidade a Drogas/epidemiologia , Rotulagem de Medicamentos , Humanos , Omalizumab , Prevalência , Vigilância de Produtos Comercializados , Doença do Soro/epidemiologia , Estados Unidos/epidemiologiaRESUMO
Based on our original pyrazine hit, CP-0809101, novel conformationally-restricted 5HT2c receptor agonists with 2-piperazin-azaindane scaffold were designed. Synthesis and structure-activity relationship (SAR) studies are described with emphasis on optimization of the selectivity against 5HT2a and 5HT2b receptors with excellent 2c potency. Orally-active and selective compounds were identified with dose-responsive in vivo efficacy in our pre-clinical food intake model.
Assuntos
Fármacos Antiobesidade/síntese química , Compostos Aza/síntese química , Agonistas do Receptor 5-HT2 de Serotonina , Agonistas do Receptor de Serotonina/síntese química , Administração Oral , Animais , Fármacos Antiobesidade/química , Fármacos Antiobesidade/farmacologia , Compostos Aza/química , Compostos Aza/farmacologia , Cães , Desenho de Fármacos , Haplorrinos , Humanos , Obesidade/tratamento farmacológico , Ratos , Receptor 5-HT2C de Serotonina/metabolismo , Agonistas do Receptor de Serotonina/química , Agonistas do Receptor de Serotonina/farmacologiaRESUMO
Brain-penetrable proline amides were developed as 5HT2c agonists with more than 1000-fold binding selectivity against 5HT2b receptor. After medicinal chemistry optimization and SAR studies, orally active proline amides with robust efficacy in a rodent food intake inhibition model were uncovered.
Assuntos
Fármacos Antiobesidade/farmacocinética , Fármacos Antiobesidade/uso terapêutico , Obesidade/tratamento farmacológico , Prolina/farmacocinética , Prolina/uso terapêutico , Agonistas do Receptor 5-HT2 de Serotonina , Administração Oral , Amidas/farmacocinética , Amidas/farmacologia , Amidas/uso terapêutico , Animais , Fármacos Antiobesidade/farmacologia , Encéfalo/metabolismo , Cães , Ingestão de Alimentos/efeitos dos fármacos , Humanos , Prolina/análogos & derivados , Prolina/farmacologia , Ratos , Receptor 5-HT2C de Serotonina/metabolismo , Relação Estrutura-AtividadeRESUMO
Synthesis and structure-activity relationship (SAR) studies on 5-trifluoromethylpyrido[4,3-d]pyrimidin-4(3H)-ones, a novel class of calcium receptor antagonists is described with particular emphasis on optimization of the pharmacokinetic/pharmacodynamic parameters required for a short duration of action compound. Orally-active compounds were identified which displayed the desired animal pharmacology (rapid and transient stimulation of parathyroid hormone) essential for bone anabolic effects.
Assuntos
Anabolizantes/química , Pirimidinonas/química , Receptores de Detecção de Cálcio/antagonistas & inibidores , Administração Oral , Anabolizantes/administração & dosagem , Anabolizantes/farmacocinética , Animais , Masculino , Hormônio Paratireóideo/metabolismo , Pirimidinonas/administração & dosagem , Pirimidinonas/farmacocinética , Ratos , Ratos Sprague-Dawley , Receptores de Detecção de Cálcio/metabolismo , Relação Estrutura-AtividadeAssuntos
Antiasmáticos/uso terapêutico , Anticorpos Anti-Idiotípicos/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Asma/terapia , Prednisona/efeitos adversos , Insuficiência Adrenal/etiologia , Insuficiência Adrenal/imunologia , Insuficiência Adrenal/terapia , Asma/imunologia , Asma/fisiopatologia , Dor nas Costas/etiologia , Dor nas Costas/imunologia , Dor nas Costas/terapia , Criança , Humanos , Masculino , Omalizumab , Prednisona/uso terapêutico , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
Hereditary angioedema (HAE) is a rare autosomal dominant disease most commonly associated with defects in C1 esterase inhibitor (C1-INH). HAE manifests as recurrent episodes of edema in various body locations. Atypical symptoms, such as ascites, acute respiratory distress syndrome, and hypovolemic shock, have also been reported. Management of HAE conventionally involves the treatment of acute attacks, as well as short- and long-term prophylaxis. Since attacks can be triggered by several factors, including stress and physical trauma, prophylactic therapy is recommended for patients undergoing surgery. Human plasma-derived C1-INH (pdC1-INH) concentrate is indicated for the treatment of both acute HAE attacks and pre-procedure prevention of HAE episodes in patients undergoing medical, dental, or surgical procedures. We report the first case of a patient with HAE who experienced an abdominal attack precipitated by a retroperitoneal bleed while being converted from warfarin to heparin in preparation for surgery. Subsequently, the patient had a protracted course in hospital with other complications, which included hypovolemic shock, ascites, severe sepsis from nosocomial pneumonia, renal and respiratory failure. Despite intensive interventions, the patient remained in a critical state for months; however, after a trial of daily intravenous infusion of pdC1-INH concentrate (Berinert®, CSL Behring GmbH, Marburg, Germany), clinical status improved, particularly renal function. Therefore, pdC1-INH concentrate may be an effective treatment option to consider for critically-ill patients with HAE.
RESUMO
BACKGROUND: Hereditary Angioedema (HAE) is a rare autosomal dominant condition characterized by episodic angioedema, which may be triggered by invasive procedures and surgery. C1 inhibitor (C1 INH) was approved in the United States and Canada in 2009 and 2010, respectively, for the treatment of acute attacks. Most recently in April 2013, it was approved in Europe for short-term prophylaxis (STP), prior to medical, dental, or surgical procedures, to prevent HAE attacks in both children and adults. Currently, C1 INH is not approved in Canada or the United States for STP of HAE attacks. Our objective was to demonstrate the effectiveness of C1 INH as a short-term prophylactic treatment for patients with Type I HAE undergoing invasive surgical procedures. METHODS: A retrospective chart review between 1997-2013 was performed at one Canadian Tertiary Care Allergy and Asthma Clinic affiliated with The Ottawa Hospital, in Ottawa, Canada. The standard dose of C1 INH for STP was 10 or 20 U/kg. RESULTS: In all 24 procedures, there were no post-procedure HAE attacks after short-term prophylactic administration of C1 INH. CONCLUSIONS: In this retrospective chart review at one tertiary care Allergy and Clinical Immunology Clinic, short-term prophylactic use of C1 INH was found to be effective at preventing post-procedure HAE attacks, in patients diagnosed with Type I HAE.